1. India Stocks

  2. •

    Process industries

  3. •

    Chemicals: specialty
Samrat Pharmachem Limited

Samrat Pharmachem Limited

BBSE:SAMRATPH
288.10
INR
+15.95
(+5.86%)
-7.15EPS
678.65MMarket Cap
Samrat Pharmachem Limited
BSE:SAMRATPH
(Bombay Stock Exchange)

Recent

price

288.10

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
140.56
225.08
228.25
209.86
152.81
200.2
230.04
299.19
359.61
444.71
579.27
717.71
1,005.42
911.35
925.2
937.7
951.72
Revenue per Share
4.34
12.23
1.3
0.78
1.02
0.98
5.68
10.41
4.97
13.71
17.26
55.62
53.83
7
23.02
-10.72
-7.15
Basic EPS, GAAP
-5.18
1.18
-10.23
10.72
-2.36
-2.85
-12.48
-0.17
6.72
-10.25
6.7
52.42
-35.27
28.3
-34.3
18.72
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
- -
Dividend per Share
28.22
40.45
41.74
42.52
43.55
43.89
49.57
59.98
64.95
78.66
95.92
151.54
204.37
210.37
232.39
220.67
- -
Book Value per Share
28.21
40.44
41.64
42.45
43.49
43.7
49.42
59.89
64.91
78.65
95.89
151.51
204.34
210.35
232.34
220.63
- -
Tangible Book Value per Share
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
Basic Weighted Avg Shares
434
695
705
648
473
619
711
924
1,111
1,374
1,790
2,218
3,106
2,816
2,859
2,897
2,938
Sales/Revenue/Turnover
5.17
8.88
1.8
1.46
1.8
1.22
4.7
5.92
2.64
4.53
4.88
10.72
7.53
0.66
3.41
-0.96
-0.72
Operating Margin (%)
2
2
2
3
4
4
4
4
4
4
5
6
6
6
7
7
7
Depreciation Expense
13
38
4
2
3
3
18
32
15
42
53
172
166
22
71
-33
-22
Net Income, GAAP
36.42
34.86
31.17
40.65
34.04
32.85
36.79
34.62
28.83
26.76
27.38
27.19
26.19
14.19
28.06
- -
- -
Effective Tax Rate (%)
3.09
5.43
0.57
0.37
0.67
0.49
2.47
3.48
1.38
3.08
2.98
7.75
5.35
0.77
2.49
-1.14
-0.75
Profit Margin (%)
58
74
66
63
64
79
92
122
134
158
200
339
459
462
538
480
- -
Working Capital
- -
13
10
7
3
15
12
8
3
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
87
125
129
131
135
136
153
185
201
243
296
468
631
650
718
682
- -
Total Equity
13.87
28.76
2.42
1.44
1.92
1.68
7.51
13.63
7.44
15.17
17.11
34.86
23.52
2.03
8.85
- -
- -
Return on Invested Capital (%)
13.87
28.76
2.42
2.52
2.93
2.65
9.84
14.35
7.64
15.82
16.67
37.62
25.44
3.4
9.62
- -
- -
Return on Capital (%)
16.68
35.61
3.15
1.86
2.38
2.23
12.15
19.01
7.96
19.1
19.77
44.95
30.25
3.38
10.4
-4.73
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
107
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3
3
3
Market Capitalization
702
602
679

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
1,038
- -
Cash, Cash Equivalents & STI
- -
63
- -
Accounts Receivable, Net
- -
510
- -
Inventories
- -
436
- -
Total Current Liabilities
- -
558
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
107
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.65%
20.24%
-5.04%
Free Cash Flow
-418.81%
-8.08%
-154.57%
Net Income, GAAP
92.94%
42.86%
-146.57%
Sales/Revenue/Turnover
17.66%
11.5%
1.35%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
808
702
637
712
2,859
2026
757
789
634
718
2,897
2027
798
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
6.69
8.61
9.01
-1.29
23.02
2026
-0.74
-1.9
-1.49
-6.59
-10.72
2027
2.84
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
1
2026
- -
- -
- -
- -
1
2027
- -
- -
- -
- -
- -
Similar Companies
Petkim Petrokimya Holding Anonim Sirketi (BIST:PETKM)
Albemarle Corporation (NYSE:ALB)
Linde plc (NASDAQ:LIN)
Gubre Fabrikalari T.A.S. (BIST:GUBRF)
IOL Chemicals & Pharmaceuticals Ltd. (NSE:IOLCP)
PI Industries Limited (NSE:PIIND)
Business
Samrat Pharmachem Limited manufactures and exports a broad range of iodine and bromine derivatives from its facilities in Ankleshwar, Gujarat, India, where it was incorporated in 1992 and listed on the Bombay Stock Exchange in 1995; the company maintains its corporate office in Mumbai. Its core products include 3-5 diiodosalicylic acid, ammonium iodide, cadmium iodide, calcium iodate, clioquinol, copper iodide, ethyl iodide, ethylenediamine dihydroiodide, hydroiodic acid, iodic acid, iodine monochloride, iodoquinol, lithium iodide, methyl iodide, N-iodosuccinimide, periodic acid, potassium iodate, potassium iodide, potassium metaperiodate, povidone iodine, selenium dioxide, sodium iodate, sodium iodide, sodium metaperiodate, sodium selenite, and trimethyl sulphoxonium iodide, serving industries such as pharmaceuticals, agrochemicals, animal nutrition, chemicals, cosmetics, food, fertilizers, salt, textiles, and tire cord manufacturing. The company exports to the United States, Europe, Africa, Asia, the Middle East, and other international markets, supplying multinational customers with facilities approved by regulators including USFDA, EU GMP, UK MHRA, Health Canada, WHO, and Brazil ANVISA. Recent developments include obtaining Authorized Economic Operator certification from Indian Customs and applying for USFDA plant approval in 2021, receiving additional production consent and expanding production lines from GPCB in 2019, earning ISO, FAMI-QS, and government-recognized Export House accreditations in 2017, alongside ongoing R&D enhancements and GMP compliance upgrades.